Axsome settles AUVELITY patent litigation with Teva; generic entry no earlier than 2038-2039

Axsome Therapeutics, Inc.

Settlement grants Teva license to sell generic AUVELITY starting Mar 31, 2039 (if pediatric exclusivity) or Sep 30, 2038 (if not).
All ongoing AUVELITY patent litigation in U.S. District Court for New Jersey will be terminated.
Agreement is subject to review by the U.S. FTC and U.S. Department of Justice.
CEO Herriot Tabuteau says settlement reflects strength of Axsome’s IP portfolio and commitment to CNS innovation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.